AI brief of an SEC Form 8-K · Bambusa Therapeutics, Inc. (BBTX)

Bambusa Therapeutics adopts new charter and bylaws as IPO completes on November 2, 2026

Neutral Impact 2 of 5 shareholder Written later

Bambusa Therapeutics filed an amended and restated certificate of incorporation with Delaware and adopted amended and restated bylaws on November 2, 2026, in connection with completing its initial public offering. The filing describes these governing documents by reference to its October 30, 2026 prospectus and attaches the full texts as exhibits.

Key points

  • Restated certificate of incorporation filed with the Delaware Secretary of State on November 2, 2026 (Exhibit 3.1)
  • Restated bylaws adopted effective November 2, 2026 (Exhibit 3.2)
  • Terms described in the prospectus filed October 30, 2026 under Registration Statement on Form S-1 (File No. 333-299405)
  • Filing also includes a Regulation FD notice that the company may use its website, social media and other channels to share material information

The filing

CompanyBambusa Therapeutics, Inc. (BBTX)
Form8-K, current report
Filed with the SECNov 2, 2026, 6:19 PM ET
Accession number0001628280-26-069027

Items reported: 5.03 Bylaw / Charter Amendment7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.